Recurrent Rectal Cancer Clinical Trial
Official title:
Phase II Trial of VEGF Trap in Patients With Previously Treated Metastatic Colorectal Cancer
Verified date | February 2024 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial is studying how well VEGF Trap works in treating patients with previously treated metastatic colorectal cancer. VEGF Trap may stop the growth of colorectal cancer by blocking blood flow to the tumor.
Status | Completed |
Enrollment | 75 |
Est. completion date | September 2012 |
Est. primary completion date | September 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - histologically/cytologically confirmed metastatic colorectal metastatic cancer - measurable disease (at least 1 lesion accurately measured in at least 1 dimension (longest diameter) as>20mm with conventional techniques or as >10mm with spiral CT scan - >=4 weeks from major surgery - at least 1prior line of systemic therapy for metastatic disease. Prior treatment with anti-epidermal growth factor receptor inhibitors is allowed. Last dose >=4 weeks prior to randomization - Two cohorts: 1) bevacizumab naïveand; 2) bevacizumab treated - May have received prior thymidylate synthetase inhibitor concurrently with radiation as "radiation sensitizer". Last dose >=4 weeks prior to randomization - Prior radiation treatment >=4 weeks prior to randomization - Age>=18 years - Life expectancy >=3 months - ECOG<=2 (Karnofsky=60%) - leukocytes >3.0x10^9/L - absolute neutrophil count >1.5 x 10^9/L - platelets>75x10^9/L - INR <1.5 unless on warfarin - total bilirubin within 1.5xULN - AST/ALT=2.5 X institution ULN - creatinine=1.5xULN OR creatinine clearance >60mL/min/1.73m2 for patients with creatinine levels above1.5x institution limits - Urinalysis negative for protein OR 24h urine for protein <500 mg - full-dose anticoagulants with PT INR >1.5 eligible provided that: a) patient is therapeutic on stable dose of warfarin or low molecular weight heparin; b) patients on warfarin, the upper target for INR is <=3; c) no active bleeding/pathological condition carrying high bleeding risk - Eligibility of patients receiving medications known to affect activity/PK of VEGF Trap will be determined by PI - Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 6 months after completion of VEGF Trap therapy - Ability to understand/willingness to sign written informed consent Exclusion Criteria: - chemotherapy/radiotherapy within 4 weeks (6 weeks for nitrosoureas/mitomycin C) prior to study entry - Other investigational agents concurrently - History of prior anti-angiogenic therapy other than bevacizumab - Evidence of CNS disease - Known hypersensitivity to Chinese hamster ovary cell products/other recombinant human antibodies, and patients with a history of allergic reactions attributed to compounds of similar chemical/biologic composition to other agents used in the study. - Serious/non-healing wound/ulcer/bone fracture - History of abdominal fistula/GI perforation/bowel obstruction/intraabdominal abscess within 28 days of treatment - major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to Day 1 therapy - anticipation of need for major surgical procedures during study - core biopsy within 7 days prior to Day 1 therapy - Patients with clinically significant cardiovascular disease - Evidence of bleeding diathesis or coagulopathy - PT INR >1.5 unless the patient is on full-dose warfarin - Use of thrombolytic agents within 1 month of study initiation - Significant Proteinuria (>500mg/24h): Urine protein should be screened by random urinalysis for protein. If dipstick positive (>1+), 24-hour urine protein should be obtained and if >500mg/24 h, patient will be excluded. - Uncontrolled intercurrent illness including but not limited to ongoing or active infection or psychiatric illness/social situations that would limit compliance with study - Pregnant women - HIV-positive patients on combination antiretroviral therapy are ineligible because of potential for PK interactions with VEGF Trap |
Country | Name | City | State |
---|---|---|---|
Canada | University Health Network-Princess Margaret Hospital | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Tumor Response (Defined as Partial or Complete Response as Defined by the RECIST Criteria) | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions:Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions | Up to 6 years | |
Primary | Progression-free Survival (Bevacizumab- naïve Group) | Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Kaplan-Meier method will be used.Progression-free survival (Bevacizumab- naïve group) |
4 months | |
Primary | Progression-free Survival (Bevacizumab-treated Group) | Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Kaplan-Meier method will be used. Progression-free survival (Bevacizumab-treated group) |
4 months | |
Secondary | Overall Survival (Bevacizumab-naïve Group) | Kaplan-Meier method will be used. (Bevacizumab- naïve Group) | 12 months | |
Secondary | Overall Survival (Prior Bevacizumab Treated Group) | Kaplan-Meier method will be used (Bevacizumab-naïve Group) | 12 months | |
Secondary | Time to Progression | Kaplan-Meier method will be used. | 12 months | |
Secondary | Objective Stable Disease Rate | Up to 6 years | ||
Secondary | Number of Participants With Response (Bevacizumab-naïve Group) | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions; Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD;
Stable disease for atleast 16 weeks |
Up to 6 years | |
Secondary | Overall Survival (Bevacizumab-treated Group) | Kaplan-Meier method will be used. (Bevacizumab-treated Group) | 6 months | |
Secondary | Overall Survival (Bevacizumab-treated Group) | Kaplan-Meier method will be used (Bevacizumab-treated Group) | 12 months | |
Secondary | Number of Participants With Response (Bevacizumab-treated Group) | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions; Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD;
Stable disease for atleast 16 weeks |
Up to 6 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01987726 -
Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
|
||
Active, not recruiting |
NCT00826540 -
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT00025337 -
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
|
Phase 3 | |
Recruiting |
NCT04642924 -
SGM-101 in Locally Advanced and Recurrent Rectal Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Completed |
NCT01217450 -
Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT01191684 -
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
|
Phase 1 | |
Terminated |
NCT01233505 -
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT01238965 -
Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy
|
Phase 1 | |
Terminated |
NCT01285102 -
Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
|
Phase 1 | |
Completed |
NCT01037790 -
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
|
Phase 2 | |
Completed |
NCT00551421 -
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00091182 -
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
|
Phase 2 | |
Terminated |
NCT00052585 -
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
|
Phase 2 | |
Completed |
NCT00023933 -
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
|
Phase 1 | |
Not yet recruiting |
NCT05076305 -
PelvEx 4: Advanced Pelvic Malignancy and the Role of the Multi-disciplinary Team Meeting
|
||
Completed |
NCT01740648 -
Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer
|
Phase 1 | |
Terminated |
NCT00397878 -
AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer
|
Phase 2 | |
Completed |
NCT00100841 -
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
|
Phase 2 | |
Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 |